Methotrexate inhibits NF-κB activity via long intergenic (noncoding) RNA-p21 induction

Arthritis and Rheumatology

Volumn 66, Issue 11, 2014, Pages 2947-2957

  Spurlock, Charles F ^a   Tossberg, John T ^a   Matlock, Brittany K ^b   Olsen, Nancy J ^c   Aune, Thomas M ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DNA DEPENDENT PROTEIN KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LONG UNTRANSLATED RNA; MESSENGER RNA; METHOTREXATE; NF KAPPA B1; P21 ACTIVATED KINASE; PROTEIN P53; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; NUCLEAR PROTEIN; PRKDC PROTEIN, HUMAN; PROTEIN KINASE R;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME INDUCTION; FEMALE; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSFORMED CELL; WESTERN BLOTTING; ARTHRITIS, RHEUMATOID; CELL CULTURE; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MONOCYTE; PATHOLOGY; T LYMPHOCYTE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL LINE; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-ACTIVATED PROTEIN KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; EIF-2 KINASE; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MONOCYTES; NF-KAPPA B; NUCLEAR PROTEINS; RNA, LONG NONCODING; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84921992712     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38805     Document Type: Article

References (39)

1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al., Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum 2008; 58: 15-25.
2. Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM, et al., Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 54-8.
3. Gabriel SE,. Why do people with rheumatoid arthritis still die prematurely? Ann Rheum Dis 2008; 67: 30-4.
4. Fujii H, Shao L, Colmegna I, Goronzy JJ, Weyand CM,. Telomerase insufficiency in rheumatoid arthritis. Proc Natl Acad Sci U S A 2009; 106: 4360-5.
5. Shao L, Fukii H, Ines C, Oishi H, Goronzy JJ, Weyand CM,. Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis. J Exp Med 2009; 206: 1435-49.
6. Shao L, Goronzy JJ, Weyand CM,. DNA-dependent protein kinase catalytic subunit mediates T-cell loss in rheumatoid arthritis. EMBO Mol Med 2010; 2: 415-27.
7. Shiloh Y,. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3: 155-68.
8. Spurlock CF III, Tossberg JT, Fuchs HA, Olsen NJ, Aune TM,. Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum 2012; 64: 1780-9.
9. Spurlock CF III, Aune ZT, Tossberg JT, Collins PL, Aune JP, Huston JW, et al., Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum 2011; 63: 2606-16.
10. Tian H, Cronstein BN,. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65: 168-73.
11. Chan SL, Cronstein BN,. Methotrexate: how does it really work? Nat Rev Rheumatol 2010; 6: 175-8.
12. Cronstein BN,. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacological Rev 2005; 57: 163-72.
13. Cronstein BN, Naime D, Ostad E,. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675-82.
14. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, et al., Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003; 48: 240-7.
15. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, et al., Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet 2011; 43: 621-9.
16. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, et al., A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010; 142: 409-19.
17. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al., Chromatin signature reveals over a thousand highly conserved large noncoding RNAs in mammals. Nature 2009; 458: 223-7.
18. Guttman M, Garber M, Levin JZ, Donaghey J, Robinson J, Adiconis X, et al., Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat Biotechnol 2010; 28: 503-10.
19. Rinn JL, Chang HY,. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012; 81: 145-66.
20. Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, et al., p53 is a suppressor of inflammatory response in mice. FASEB J 2005; 19: 1030-2.
21. Pahl HL,. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18: 6853-66.
22. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, et al., Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013; 23: 634-46.
23. Ak P, Levine AJ,. p53 and NF-κB: different strategies for responding to stress lead to a functional antagonism. FASEB J 2010; 24: 3643-52.
24. Gudkov AV, Komarova EA,. Pathologies associated with the p53 response. Cold Spring Harb Perspect Biol 2010; 2: a001180.
25. Combe B, Edno L, Lafforgue P, Bologna C, Bernard JC, Acquaviva P, et al., Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol 1995; 34: 421-8.
26. Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale JL, De S, et al., LincRNA-p21 suppresses target mRNA translation. Mol Cell 2012; 47: 648-55.
27. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al., 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
28. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
29. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
30. Maas K, Chan S, Parker J, Slater A, Moore J, Olsen N, et al., Cutting edge: molecular portrait of human autoimmune disease. J Immunol 2002; 169: 5-9.
31. Wang L, Zhang B, Wolfinger RD, Chen X,. An integrated approach for the analysis of biological pathways using mixed models. PLoS Genet 2008; 4: e1000115.
32. Eaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS,. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest 2007; 117: 2723-34.
33. Li Y, Yang DQ,. The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt. Mol Cancer Ther 2010; 9: 113-25.
34. Gapud EJ, Dorsett Y, Yin B, Callen E, Bredemeyer A, Mahowald GK, et al., Ataxia telangiectasia mutated (Atm) and DNA-PKcs kinases have overlapping activities during chromosomal signal joint formation. Proc Natl Acad Sci U S A 2011; 108: 2022-7.
35. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, et al., Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006; 66: 5354-62.
36. Oksenych V, Kumar V, Liu XY, Guo CG, Schwer B, Zha S, et al., Functional redundancy between the XLF and DNA-PKcs DNA repair factors in V(D)J recombination and nonhomologous DNA end joining. Proc Natl Acad Sci U S A 2013; 110: 2234-9.
37. Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr., Tumor necrosis factor α-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000; 275: 32592-7.
38. Liu S, Opiyo SO, Manthey K, Glanzer JG, Ashley AK, Amerin C, et al., Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress. Nucleic Acids Res 2012; 40: 10780-94.
39. Yang F, Zhang H, Mei Y, Wu M,. Reciprocal regulation of HIF-1α and lincRNA-p21 modulates the Warburg effect. Mol Cell 2014; 53: 88-100.